<SEC-DOCUMENT>0001564590-16-025688.txt : 20161006
<SEC-HEADER>0001564590-16-025688.hdr.sgml : 20161006
<ACCEPTANCE-DATETIME>20161006160552
ACCESSION NUMBER:		0001564590-16-025688
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161006
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161006
DATE AS OF CHANGE:		20161006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		161924961

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abio-8k_20161006.htm
<DESCRIPTION>ABIO-8K-20161006
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-8k_20161006.htm
</title>
</head>
<!-- NG Converter v4.0.3.7 -->
<body>

<p style="text-align:justify;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): October 6, 2016 (October 6, 2016)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">000-22873</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Road, Suite 140, Westminster, CO 80020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices) (Zip Code)</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(720) 940-2200</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><a name="OLE_LINK9"></a><a name="OLE_LINK10"></a><font style="font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:4pt;border-top:Solid 0.75pt #000000;padding-top:0pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> &#8212; </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Events</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.01.</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Events. </p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 6, 2016, ARCA biopharma, Inc. (&#8220;ARCA&#8221;) provided a GENETIC-AF clinical trial update.&nbsp;&nbsp;The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 9 &#8212; Financial Statements and Exhibits </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:78.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press Release titled &#8220;ARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial&#8221; dated October 6, 2016.</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:62.25%;"></td>
<td style="width:4.17%;"></td>
<td style="width:5.5%;"></td>
<td style="width:28.08%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: October 6, 2016</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Chief Accounting Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO EXHIBITS </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:78.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press Release titled &#8220;ARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial&#8221; dated October 6, 2016.</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>abio-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex991_6.htm
</title>
</head>
<!-- NG Converter v4.0.3.7 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2dtuks1vvj0000001.jpg" title="" alt="" style="width:203px;height:69px;"></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:48.89%;"><br>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARCA biopharma announces randomization of first european patients in GENETIC-AF phase 2b/3 clinical trial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">------------------------------------------------------------------------------- </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Approximately Six Million Patients in Europe Estimated to Have Atrial Fibrillation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">------------------------------------------------------------------------------- </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Geographic Expansion of Trial Intended to Support European Regulatory Submissions, European Partnering Discussions and Enrollment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>Westminster, CO, October 6, 2016<font style="font-style:normal;"><a name="OLE_LINK5"></a><a name="OLE_LINK6"></a> &#8211; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to the development of genetically-targeted therapies for cardiovascular diseases, today announced the randomization of the first European patients in the GENETIC-AF Phase 2B/3 clinical trial.&nbsp;&nbsp;GENETIC-AF, which has been enrolling patients in the United States and Canada, is evaluating Gencaro<sup style="font-size:85%; vertical-align:top">TM</sup> as a potential treatment for atrial fibrillation (AF).&nbsp;&nbsp;Last week, ARCA hosted a GENETIC-AF European Investigator Meeting which brought together European physicians and research coordinators for study-specific training and information sharing.&nbsp;&nbsp;It is estimated that approximately six million patients in Europe have atrial fibrillation. </font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA is evaluating Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the GENETIC-AF Phase 2B/3 clinical trial.&nbsp;&nbsp;ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted therapy for the prevention of atrial fibrillation.</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are excited to expand the GENETIC-AF trial to European investigative sites that have expressed interest in participating in the on-going trial,&#8221; said Michael R. Bristow, President and Chief Executive Officer.&nbsp;&nbsp;&#8220;We expect that the additional investigative sites in certain European countries will support the latter part of Phase 2B, and potentially the Phase 3 stage, of the trial.&nbsp;&nbsp;We believe inclusion of European investigative sites may also support potential European regulatory submissions and on-going business development activity.&#8221;</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the current enrollment rate, the Company expects to randomize at least 150 patients into the trial by the end of 2016. The GENETIC-AF Data Safety Monitoring Board (DSMB) will conduct an interim efficacy, safety and futility analysis of data from at least 150 patients with evaluable data. The Company expects the outcome of this interim analysis in the second quarter of 2017.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About ARCA biopharma</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach to drug development.  The Company's lead product candidate, Gencaro<sup style="font-size:85%; vertical-align:top">TM</sup> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation.  ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment.&nbsp;&nbsp;ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial.&nbsp;&nbsp;For more information, please visit <font style="text-decoration:underline;">www.arcabio.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Safe Harbor Statement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.&nbsp;&nbsp;These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, potential timeline for GENETIC-AF trial activities, the potential for any European regulatory submissions for Gencaro, the potential outcome of the GENETIC-AF Phase 2B interim analysis, the sufficiency of the Company&#8217;s capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro&#8217;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment.&nbsp;&nbsp;Such statements are based on management's current expectations and involve risks and uncertainties.&nbsp;&nbsp;Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#8217;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes.&nbsp;&nbsp;These and other factors are identified and described in more detail in ARCA&#8217;s filings with the SEC, including without limitation the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2015, and subsequent filings.&nbsp;&nbsp;The Company disclaims any intent or obligation to update these forward-looking statements<font style="font-style:normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investor &amp; Media Contact:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derek Cole<font style="margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">720.940.2163</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">derek.cole@arcabio.com</font> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Tables Follow)</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g2dtuks1vvj0000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2dtuks1vvj0000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "> =$# 2(  A$! Q$!_\0
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MI_X* >/5\*^#=1U>RFU HT>C^#8#8B!00ID>Y!,R1Y9=[23",9&<"O:?A/\
M\&\WC_XJ,=>^+/Q)M](U;4#'<36]K&^LWK[AEUGN)'15E4\93SE)R0Q'6/:-
M[(OV=MV?I)?_ +;'P;TJ;R[KXM?#.VDR1ME\46*-D=1@RUL>%_VE?AWXXNUM
M]%\>^"]8N&SB.RUNVN'..O".3W'YU\;Q?\&Y/P16,!O$_P 46;')_M*Q'/\
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M>6[V]Q"=KHXZ>GU!'((X(.15?1-+R!7M/PN;3O'NFV_AWQ!^[EC&S3+\?ZR
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M.@I=?M+>/M2X\RS\,K:J>^);J)C_ .B17['"JI;$U'J%%%%:&84444 %%%%
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MVEW&KI<0Z-"7#RZ9 ZI' 2%<Q[HE4,P4@,[''.*^\%_X. ?B B@+^SQJ"@<
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M $__ *4&OSH\*V,>J>)]-M9EW0W%U%%( <95G //T-?HO_P<G_\ )>/AO_V
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MM)59->G+!?FF?F_&4D\<DND5^;?ZA1103@5^P'R8C?=K\$/^"JWQ^U#]M_\
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M)J6AV;1^ /&CR7FD%%'EZ?-G,UG[!"0R<?<=1DE&-8U(]4;4Y=#[;_X(4?\
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MFZC<6%AK,VB7=^]W$CLB7,;Y6##@!Q\KJ P&6ZG]%.M&*]"2N8Q=C\'?B/\
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M'CG!KI=M &*N,;$2E?H0WMA!J5G-;W$,5Q;W"&.6*1 R2*1@JP/!!'!!ZU\
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MQU;P$*9M3\+7)NBN. );8HIQ_>96/)R2:_6;&:,4>SMLP]I?='Y]_P##SO\
M::_Z-*\4?]_;K_Y'HK]!,457*^XN9=@HHHJB VT=*** "BBB@ HHHH *,444
M &WFBBB@ HHHH ***#TH ,XK/M_%6F7>O3:5#J%E+J=O&)I;1)E::)"<;F3.
M0,D<D=Z^;?V_M>\4^!!9W5CXSOK73]9D,,>DVZ"W:)4C7>WFH0[J6/(;IO Z
M5O?\$]?A@WASX97?B2ZC;[=XDGS&SCYA!&2 <GGYG+GW 4UGS^]RFGL_=YCZ
M$HHHK0S#- .:1N17QY\'?%WQAN?VFK>WU1O$#0->$:E;W"/]AAM\G<R@_(H
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MRNKG/*-G8GU[Q#I_A?3)+S5+ZSTVSC(#SW4RPQ(2<#+,0!DG%1^'/%.E^,;
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M9_ZZ#WJO:/FL+V:Y;W/KRBBLGQOXWTOX=^&;K6-8NX[.PLUW22/W]% ZEB>
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:0@,",CUJWLQ2T4 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
